title: [Pharmacokinetics and relative bioavailability of neostigmine bromide sustained-release tablets].
abstract: OBJECTIVE
  To study the pharmacokinetics and relative bioavailability of neostigmine bromide conventional tablets and sustained-release tablets in rabbits.
  
  
  METHODS
  Six healthy rabbits were randomly divided into two groups for a cross self-contrast trial. RP-HPLC was used to detect plasma concentrations of neostigmine bromide. The pharmacokinetic parameters were calculated with the aid of DAS 2.0 software.
  
  
  RESULTS
  The main pharmacokinetics parameters of the sustained-release tablets and conventional tablets were as follows, respectively: T(max)(3.67 +/- 1.51) hand (1.58 +/- 0.38) h; C(max) (5.04 +/- 1.19) mg/L and (4.56 +/- 1.70) mg/L; AUC(0 --> infinity) (32.82 +/- 9.88) mg/L x h and (29.84 +/- 14.27) mg/L x h. The relative bioavailability of the neostigmine bromide sustained-release tablets was 115.4%.
  
  
  CONCLUSIONS
  The pharmacokinetics of neostigmine bromide accords with two compartments model, showing constant plasma concentration and relatively high bioavailability.
authors: Medicine Engineering Research Center, Chongqing Key Laboratory of Biochemical & Molecular Pharmacology, Chongqing Medical University, Chongqing 400016, China.
authors: Hua-Rong
authors: HR
authors: Xiong
authors: Qun-You
authors: QY
authors: Tan
authors: Bi-Lin
authors: BL
authors: Liu
authors: Wen
authors: W
authors: Luo
authors: Jing-Qing
authors: JQ
authors: Zhang
mesh_terms: D000818:Animals; D001682:Biological Availability; D003692:Delayed-Action Preparations / Q000378:metabolism / Q000493:pharmacokinetics*; D005260:Female; D008297:Male; D009388:Neostigmine / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics*; D011817:Rabbits; D011897:Random Allocation; D013607:Tablets
chemical_list: D003692:Delayed-Action Preparations; D013607:Tablets; D009388:Neostigmine